Tiziana Life Sciences Expands Access To Foralumab For na-SPMS Patients

Tiziana Life Sciences has expanded its Intermediate Size Patient Population Expanded Access (ISPPEA) program for non-active secondary progressive multiple sclerosis (na-SPMS), dosing four additional patients. This brings total enrollment to 14, with the first 10 patients showing stability or improvement within six months of starting intranasal foralumab, the company’s investigational anti-CD3 monoclonal antibody therapy. 

Ivor Elrifi, CEO of Tiziana Life Sciences, stated, “We are pleased to reach this milestone of enrolling 14 patients in our na-SPMS expanded access program. This underscores our commitment to addressing the unmet medical needs of patients with na-SPMS, particularly those not eligible for our ongoing Phase 2a clinical trial. We remain dedicated to advancing our therapies and look forward to further evaluating their potential through expanded access and clinical trials.”

Tiziana’s expanded access initiative delivers therapeutic care to patients whose conditions exclude them from current Phase 2a clinical trial participation. Patients who usually cannot join na-SPMS clinical research studies gain access to treatment through this program. Tiziana remains committed to developing innovative immunomodulation therapies for neuroinflammatory diseases, including na-SPMS, Alzheimer’s disease, and ALS, as part of its broader research and development strategy.